In This Issue
Cancer Discov December 1 2015 5 (12) 1225-1227; DOI:10.1158/2159-8290.CD-ITI5-12
Amplification of RICTOR is present in 8–13% of patients with lung cancer and is associated with a greater response to mTORC1/2 inhibition.
Resistance to MET inhibition in MET-amplified esophagogastric cancer is mediated by KRAS mutation, coamplification of HER2 and/or EGFR, and intratumor heterogeneity in MET amplification.
Alternative splicing of CD19 prevents its recognition by CD19-targeted chimeric antigen receptor (CAR) T cells and can underlie resistance to CD19 CAR T-cell therapy in patients with B-ALL.
Integrated mRNA and miRNA profiling of mouse and human pancreatic neuroendocrine tumors (PanNET) identifies distinct subtypes and validates the RIP1-Tag2 mouse model as representative of human PanNET.
The prometastatic and oncogenic functions of RNF2 in melanoma are driven by differential changes in gene expression regulated by chromatin modification or recruitment of transcriptional activators, respectively.
Delayed exposure to infection promotes B-cell precursor acute lymphoblastic leukemia in the context of inactivating germline Pax5 mutations, which create an aberrant progenitor cell compartment that is susceptible to Jak3 mutation–induced transformation.